Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Skip to Content

Zanubrutinib (Brukinsa®) Patient Selection and Management in Mantle Cell Lymphoma – 2

Download PQI pdf 1.59MB

Last Updated: October 1, 2021

By: Arizona Blood and Cancer Specialists, AZ | Kootenai Health, ID

About this PQI in Action

Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin’s lymphoma (NHL). MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone, thus being named mantle cell lymphoma.1 In general MCL is most common among men aged 60 to 70 years of age. According to the National Institute of Health (NIH), MCL is a rare subtype of B-cell NHL with an annual incidence of one case per 200,000 people.2 Many people are asymptomatic during the early stages of MCL. When symptomatic, MCL most commonly manifests with painless swelling of lymph nodes of Waldeyer’s ring. This is a ring of lymphoid tissue around the base of the tongue, either side of the throat, tonsils and the back of the nasal cavity.1,2 Other symptoms may be non-specific, including lack of appetite, nausea, early satiety, abdominal swelling/bloating. Being a B-cell cancer, it comes as no surprise that other symptoms may include what is commonly referred to as “B Symptoms.” These include fever, unexplained weight loss, and night sweats. Diagnosis is achieved through a myriad of tests: lymph node and bone marrow biopsy, imaging, FISH, and flow cytometry. Traditionally, first line therapy consists of combination chemotherapy regimens of varying mechanisms. Bruton’s tyrosine kinase (BTK) inhibitors are reserved for second-line and subsequent therapy options.